Darolutamide Plus Hormone Therapy for Prostate Cancer in China
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older
- Your prostate cancer came back after at least 6 months of hormone therapy plus bicalutamide (a prior prostate cancer drug)
- You have no signs of cancer spread to other parts of your body (confirmed by imaging scans)
- Your testosterone level is very low (below 1.7 nmol/L), showing hormone therapy is working
- Your doctor has decided to treat you with hormone therapy plus darolutamide as part of routine care
- You are in good enough health to participate (ECOG score 0 or 1, meaning you can do most normal activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
This study tests a drug called darolutamide combined with standard hormone therapy for men whose prostate cancer has spread to other parts of the body and still responds to hormone treatment. The goal is to see if this combination helps control the cancer better than hormone therapy alone.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
This study looks at whether combining the drug darolutamide with standard hormone therapy can help men whose prostate cancer was found in their pelvic lymph nodes after prostate removal surgery. It aims to see if this treatment helps keep the cancer from coming back.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
Hear when a new Non-metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.